Companies Nuvalent, Inc.
Nuvalent (NUVL): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Nuvalent, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers27th pct.Of 11 peer CEOs
CEO pay, last three years
- $9,376,872FY2023
- $17,279,869FY2024
- $11,393,602FY2025
CEO total pay was $11,393,602 in fiscal 2025, down from $17,279,869 in fiscal 2024.
FY2025: salary $652,100 · bonus $0 · stock awards $4,392,563 · option awards $5,857,906
Executives and directors
Alexandra Balcom · CFOChristopher Turner · Chief Medical OfficerDarlene Noci · Chief Development OfficerJames Porter · CEODeborah Miller · General CounselAndrew A. F. Hack, M.D., Ph.D · Former director (through FY2025)Anna Protopapas · Independent DirectorCameron A. Wheeler, Ph.D · Independent DirectorChristy Oliger · Independent DirectorEmily Drabant Conley, Ph.D · Former director (through FY2025)Gary Gilliland, M.D., Ph.D · Former director (through FY2025)Grant C. Bogle · Independent DirectorJoseph Pearlberg, M.D., Ph.D · Independent DirectorMatthew Shair, Ph.D · Former director (through FY2025)Michael L. Meyers, M.D., Ph.D · Independent DirectorRon Squarer · Independent DirectorSapna Srivastava, Ph.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Nuvalent, Inc. in fiscal 2025?
As disclosed, James Porter (President and Chief Executive Officer) was the highest-paid executive at Nuvalent, Inc. in fiscal 2025, with total compensation of $11,393,602.
How does Nuvalent, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, James Porter's total compensation ranked at the 27th percentile of Nuvalent, Inc.'s disclosed peer group.
What is Nuvalent, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Nuvalent, Inc.'s CEO-to-median employee pay ratio was 21:1.
How did shareholders vote on Nuvalent, Inc.'s executive compensation?
As disclosed, 97.47% of shareholders supported Nuvalent, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Nuvalent, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Nuvalent, Inc. reported total board compensation of $2,695,640 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| James Porter | $652,100 | $0 | $4,392,563 | $5,857,906 | $469,512 | $0 | $21,521 | $11,393,602 |
| President and Chief Executive Officer | ||||||||
| Christopher Turner | 520,100 | 0 | 1,464,188 | 1,952,635 | 280,854 | 0 | 21,521 | 4,239,298 |
| Chief Medical Officer | ||||||||
| Alexandra Balcom | 475,500 | 0 | 1,464,188 | 1,952,635 | 256,770 | 0 | 21,521 | 4,170,614 |
| Chief Financial Officer and Treasurer | ||||||||
| Darlene Noci | 467,400 | 0 | 1,464,188 | 1,952,635 | 252,396 | 0 | 21,521 | 4,158,140 |
| Chief Development Officer | ||||||||
| Deborah Miller | 467,000 | 0 | 1,464,188 | 1,952,635 | 252,180 | 0 | 21,521 | 4,157,524 |
| Chief Legal Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| James Porter | $11,393,602 | $17,279,869 | $9,376,872 | ↓ −5,886,267 |
| Christopher Turner | 4,239,298 | 5,550,940 | 3,603,207 | ↓ −1,311,642 |
| Alexandra Balcom | 4,170,614 | 5,486,590 | 3,541,647 | ↓ −1,315,976 |
| Darlene Noci | 4,158,140 | — | — | — |
| Deborah Miller | 4,157,524 | 5,461,540 | — | ↓ −1,304,016 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract and retain qualified and talented executives, motivate such executives to achieve our corporate goals and reward them for short- and long-term performance with a simple and clear compensation structure.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| James Porter | RSU | 2025-01-06 | — | — | 56,250 | — | $4,392,563 |
| Alexandra Balcom | RSU | 2025-01-06 | — | — | 18,750 | — | 1,464,188 |
| Deborah Miller | RSU | 2025-01-06 | — | — | 18,750 | — | 1,464,188 |
| James Porter | OPTION | 2025-01-06 | — | — | 112,500 | — | 5,857,906 |
| Darlene Noci | RSU | 2025-01-06 | — | — | 18,750 | — | 1,464,188 |
| Christopher Turner | RSU | 2025-01-06 | — | — | 18,750 | — | 1,464,188 |
| Darlene Noci | OPTION | 2025-01-06 | — | — | 37,500 | — | 1,952,635 |
| Alexandra Balcom | OPTION | 2025-01-06 | — | — | 37,500 | — | 1,952,635 |
| Christopher Turner | OPTION | 2025-01-06 | — | — | 37,500 | — | 1,952,635 |
| Deborah Miller | OPTION | 2025-01-06 | — | — | 37,500 | — | 1,952,635 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| James Porter | $4,392,563 | $0 | $5,857,906 | 0.0% |
| Alexandra Balcom | 1,464,188 | 0 | 1,952,635 | 0.0% |
| Deborah Miller | 1,464,188 | 0 | 1,952,635 | 0.0% |
| Darlene Noci | 1,464,188 | 0 | 1,952,635 | 0.0% |
| Christopher Turner | 1,464,188 | 0 | 1,952,635 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Darlene Noci | Option | 1,162 | 18.93 | — |
| Christopher Turner | Option | 2,229 | 18.93 | — |
| Alexandra Balcom | Option | 2,229 | 18.93 | — |
| Deborah Miller | Option | 2,229 | 18.93 | — |
| Christopher Turner | PSU | 5,600 | — | 563,304 |
| Alexandra Balcom | PSU | 5,600 | — | 563,304 |
| Deborah Miller | PSU | 5,600 | — | 563,304 |
| James Porter | Option | 6,883 | 18.93 | — |
| Darlene Noci | Option | 8,333 | 14.4 | — |
| James Porter | PSU | 16,900 | — | 1,699,971 |
| Christopher Turner | RSU | 18,750 | — | 1,886,063 |
| Alexandra Balcom | RSU | 18,750 | — | 1,886,063 |
| Deborah Miller | RSU | 18,750 | — | 1,886,063 |
| Christopher Turner | RSU | 22,200 | — | 2,233,098 |
| Alexandra Balcom | RSU | 22,200 | — | 2,233,098 |
| Deborah Miller | RSU | 22,200 | — | 2,233,098 |
| Christopher Turner | Option | 24,740 | 72.35 | — |
| Alexandra Balcom | Option | 24,740 | 72.35 | — |
| Deborah Miller | Option | 24,740 | 72.35 | — |
| Christopher Turner | Option | 28,906 | 78.09 | — |
| Alexandra Balcom | Option | 28,906 | 78.09 | — |
| Deborah Miller | Option | 28,906 | 78.09 | — |
| Christopher Turner | Option | 39,054 | 27.85 | — |
| Alexandra Balcom | Option | 39,054 | 27.85 | — |
| Deborah Miller | Option | 39,054 | 27.85 | — |
| James Porter | RSU | 56,250 | — | 5,658,188 |
| James Porter | RSU | 75,200 | — | 7,564,368 |
| James Porter | Option | 83,906 | 72.35 | — |
| James Porter | Option | 86,719 | 78.09 | — |
| James Porter | Option | 113,961 | 27.85 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Matthew Shair, Ph.DIndependent · Departed during FY | $39,489 | $199,928 | $200,004 | $0 | $200,000 | $639,421 |
| Christy OligerIndependent · Audit · Newly elected | 27,715 | 299,930 | 300,021 | 0 | — | 627,666 |
| Ron SquarerIndependent · Nominating and Corporate Governance · Newly elected | 2,511 | 299,984 | 299,957 | 0 | — | 602,452 |
| Anna ProtopapasIndependent · Compensation | 85,500 | 199,928 | 200,004 | 0 | — | 485,432 |
| Sapna Srivastava, Ph.DIndependent · Audit (Chair) | 62,000 | 199,928 | 200,004 | 0 | — | 461,932 |
| Cameron A. Wheeler, Ph.DIndependent · Audit · Compensation | 54,830 | 199,928 | 200,004 | 0 | — | 454,762 |
| Michael L. Meyers, M.D., Ph.DIndependent · Nominating and Corporate Governance (Chair) | 52,000 | 199,928 | 200,004 | 0 | — | 451,932 |
| Grant C. BogleIndependent · Compensation (Chair) | 49,995 | 199,928 | 200,004 | 0 | — | 449,927 |
| Joseph Pearlberg, M.D., Ph.DIndependent · Nominating and Corporate Governance · Not standing for re-election | 47,000 | 199,928 | 200,004 | 0 | — | 446,932 |
| Gary Gilliland, M.D., Ph.DIndependent · Audit · Departed during FY | 24,285 | — | 297,937 | 0 | — | 322,222 |
| Emily Drabant Conley, Ph.DIndependent · Compensation · Departed during FY | 26,620 | — | 22,879 | 0 | — | 49,499 |
| Andrew A. F. Hack, M.D., Ph.DIndependent · Audit · Departed during FY | 24,285 | — | — | 0 | — | 24,285 |
| James R. Porter, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $42,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $496,230 |
| Equity awards (grant-date value) | $1,999,410 |
| All other compensation | $200,000 |
| Total cost of the board | $2,695,640 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Nuvalent as a peer
Companies that benchmark against NUVL
9 companies name NUVL as a compensation peer
- Apogee Therapeutics, Inc.APGEFY2025
- Cogent Biosciences, Inc.COGTFY2025
- Dyne Therapeutics, Inc.DYNFY2025
- IDEAYA Biosciences, Inc.IDYAFY2025
- Immunovant, Inc.IMVTFY2026
- Janux Therapeutics, Inc.JANXFY2025
- Kura Oncology, Inc.KURAFY2025
- Kymera Therapeutics, Inc.KYMRFY2025
- Revolution Medicines, Inc.RVMDFY2025
Each company listed discloses NUVL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NUVL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CRSP CRISPR Therapeutics AGACLX Arcellx, Inc.CYTK Cytokinetics, IncorporatedSMMT Summit Therapeutics Inc.IMVT Immunovant, Inc.MDGL Madrigal Pharmaceuticals, Inc.RNAM Avidity Biosciences, Inc.DNLI Denali Therapeutics Inc.ARWR Arrowhead Pharmaceuticals, Inc.RVMD Revolution Medicines, Inc.PCVX Vaxcyte, Inc.
Peer reciprocity
The companies Nuvalent, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Summit Therapeutics Inc. | 2025 | Mahkam Zanganeh | $616,500 | $0 | $245,021,384 | $0 | $246,047,279 |
| 2 | Arcellx, Inc. | 2024 | Rami Elghandour | 653,288 | 9,342,069 | 10,850,151 | 0 | 21,402,668 |
| 3 | Immunovant, Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 4 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 5 | Revolution Medicines, Inc. | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 6 | Vaxcyte, Inc. | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 7 | Avidity Biosciences, Inc. | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 8 | Cytokinetics, Incorporated | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 9 | Nuvalent, Inc. | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 10 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 11 | Crispr Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 12 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Nuvalent, Inc. | 120% | not disclosed | No | Alpine Rewards |
| Arcellx, Inc. | 140% | not disclosed | No | Meridian Compensation Partners |
| Arrowhead Pharmaceuticals, Inc. | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Avidity Biosciences, Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine Rewards, LLC |
| Crispr Therapeutics AG | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Cytokinetics, Incorporated | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Revolution Medicines, Inc. | 146% | Option 70 · RSU 30 | not disclosed | Compensia |
| Summit Therapeutics Inc. | 105% | Options 100 | not disclosed | not disclosed |
| Vaxcyte, Inc. | 105% | not disclosed | not disclosed | Pay Governance |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 68,898,711 | 1,786,465 | 17,926 | 97.47% | Passed |
| 2025 | 2025-06-18 | 53,520,192 | 10,356,887 | 2,498 | 83.79% | Passed |
| 2024 | 2024-06-12 | 55,798,941 | 1,324,379 | 1,837 | 97.68% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-16 | 97.47%a |
| 2025 | 2025-06-18 | 83.79%b |
| 2024 | 2024-06-12 | 97.68%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 21 : 1 |
|---|---|
| CEO total compensation | $11,393,602 |
| Median employee compensation | $540,474 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Porter | Director | 2026-05-04 | A | 30,000 | $19 | $567,900 | Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 2,111 | 103 | 217,180 | Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 17,353 | 102 | 1,771,741 | Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 7,429 | 101 | 753,895 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,300 | 106 | 138,138 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 5,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 900 | 108 | 97,326 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 1,530 | 107 | 164,399 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 5,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,178 | 108 | 127,236 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 1,401 | 106 | 148,954 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 1,669 | 109 | 182,422 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | A | 5,500 | 7 | 37,895 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,422 | 107 | 152,623 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 100 | 110 | 10,976 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,500 | 109 | 163,950 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | A | 5,500 | 28 | 153,175 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 960 | 95 | 91,075 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 200 | 104 | 20,768 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 279 | 102 | 28,399 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 2,588 | 101 | 260,482 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 3,133 | 100 | 312,861 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 900 | 98 | 87,912 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 2,170 | 96 | 208,298 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | A | 11,430 | 7 | 78,753 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 11,430 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 1,200 | 99 | 118,284 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 3,036 | 90 | 272,117 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 14,469 | 89 | 1,284,703 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 12,495 | 88 | 1,099,185 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | A | 30,000 | 19 | 567,900 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-09 | — | 685 | — | — | 1 insider, 1 accrual row | ||
| Darlene Noci | Chief Development Officer | 2026-06-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | D | 20,000 | 123 | 2,456,200 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | A | 9,315 | 19 | 176,333 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | A | 10,000 | 1 | 10,800 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | D | 9,315 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | A | 685 | 7 | 4,720 | Common | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common, indirect | Form 4 ↗ |
| James E. Flynn | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-29 | A | 5,500 | 28 | 153,175 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-29 | D | 5,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-29 | D | 5,500 | 124 | 679,305 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | A | 6,046 | 19 | 114,451 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | D | 5,384 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | D | 11,430 | 124 | 1,412,519 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | A | 5,384 | 7 | 37,096 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | D | 13,854 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | D | 9,146 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | D | 23,000 | 124 | 2,842,570 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | A | 13,854 | 72 | 1,002,337 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | A | 9,146 | 19 | 173,134 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | D | 6,046 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-06 | D | 30,000 | 124 | 3,711,600 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-06 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-06 | A | 30,000 | 19 | 567,900 | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-09 | D | 2,111 | 124 | 261,363 | Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 31,530 | 124 | 3,909,720 | Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common, indirect | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 5,577 | — | — | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 3,444 | — | — | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 47,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 18,534 | 124 | 2,298,216 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 33,423 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 121,350 | — | — | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 3,444 | — | — | Common, indirect | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 4,851 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 75,154 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 61,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 72,608 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 46,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 112,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 131,494 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 118,686 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 867,172 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 49,401 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 508,942 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 40,025 | — | — | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | A | 40,025 | 0 | 0 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 203,529 | 124 | 25,237,596 | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 18,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 9,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 8,309 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 2,113 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 22,393 | 124 | 2,776,732 | Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 19,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 12,025 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 15,052 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 17,848 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 731 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 29,433 | — | — | Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | A | 7,120 | 0 | 0 | Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 21,092 | 124 | 2,615,408 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 33,646 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 81,329 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 21,259 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 15,112 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 6,091 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 216 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 17,017 | 124 | 2,110,108 | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 47,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 144,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 2,835 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-07-15 | D | 4,418 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-07-15 | D | 6,281 | — | — | Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-07-15 | D | 6,119 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-07-15 | D | 6,091 | — | — | Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-07-15 | D | 1,324 | 124 | 164,176 | Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 68,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 3,444 | — | — | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 33,646 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 84,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 22,933 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 8,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 131,637 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 44,433 | 124 | 5,509,692 | Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 8,361 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 3,444 | — | — | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 43,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 43,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 2,717,627 | 124 | 336,985,748 | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 2,717,627 | 124 | 336,985,748 | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 3,444 | 124 | 427,056 | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 650,000 | 124 | 80,600,000 | Common, indirect | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 8,299,225 | 124 | 1,029,103,900 | Common, indirect | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 8,299,225 | 124 | 1,029,103,900 | Common, indirect | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 3,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 107,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 303,105 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 161,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 43,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 3,714 | 124 | 460,536 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 21,073 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 8,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 7,120 | — | — | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 200 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Porter | Director | 2026-05-04 | A | 30,000 | $19 | $567,900 | Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 2,111 | 103 | 217,180 | Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 17,353 | 102 | 1,771,741 | Common | Form 4 ↗ |
| James Porter | Director | 2026-05-04 | D | 7,429 | 101 | 753,895 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,300 | 106 | 138,138 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 5,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 900 | 108 | 97,326 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 1,530 | 107 | 164,399 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 5,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,178 | 108 | 127,236 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 1,401 | 106 | 148,954 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | D | 1,669 | 109 | 182,422 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-05-28 | A | 5,500 | 7 | 37,895 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,422 | 107 | 152,623 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 100 | 110 | 10,976 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | D | 1,500 | 109 | 163,950 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-05-28 | A | 5,500 | 28 | 153,175 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 960 | 95 | 91,075 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 200 | 104 | 20,768 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 279 | 102 | 28,399 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 2,588 | 101 | 260,482 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 3,133 | 100 | 312,861 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 900 | 98 | 87,912 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 2,170 | 96 | 208,298 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | A | 11,430 | 7 | 78,753 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 11,430 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-06-01 | D | 1,200 | 99 | 118,284 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 3,036 | 90 | 272,117 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 14,469 | 89 | 1,284,703 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | D | 12,495 | 88 | 1,099,185 | Common | Form 4 ↗ |
| James Porter | Director | 2026-06-08 | A | 30,000 | 19 | 567,900 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | D | 685 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | D | 20,000 | 123 | 2,456,200 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | A | 9,315 | 19 | 176,333 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | A | 10,000 | 1 | 10,800 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | D | 9,315 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-09 | A | 685 | 7 | 4,720 | Common | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common, indirect | Form 4 ↗ |
| James E. Flynn | Director | 2026-06-16 | A | 3,444 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-29 | A | 5,500 | 28 | 153,175 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-29 | D | 5,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-06-29 | D | 5,500 | 124 | 679,305 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | A | 6,046 | 19 | 114,451 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | D | 5,384 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | D | 11,430 | 124 | 1,412,519 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | A | 5,384 | 7 | 37,096 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | D | 13,854 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | D | 9,146 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | D | 23,000 | 124 | 2,842,570 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | A | 13,854 | 72 | 1,002,337 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-01 | A | 9,146 | 19 | 173,134 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-01 | D | 6,046 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-06 | D | 30,000 | 124 | 3,711,600 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-06 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-06 | A | 30,000 | 19 | 567,900 | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-09 | D | 2,111 | 124 | 261,363 | Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 31,530 | 124 | 3,909,720 | Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common, indirect | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 5,577 | — | — | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 3,444 | — | — | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 47,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 18,534 | 124 | 2,298,216 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 33,423 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 121,350 | — | — | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 3,444 | — | — | Common, indirect | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 4,851 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 75,154 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 61,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 72,608 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 46,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 112,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 131,494 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 118,686 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 867,172 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 49,401 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 508,942 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 40,025 | — | — | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | A | 40,025 | 0 | 0 | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 203,529 | 124 | 25,237,596 | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 18,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 9,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 8,309 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 2,113 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 22,393 | 124 | 2,776,732 | Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 19,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 12,025 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 15,052 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 17,848 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 8,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 731 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 29,433 | — | — | Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | A | 7,120 | 0 | 0 | Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 21,092 | 124 | 2,615,408 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 33,646 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 81,329 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 21,259 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 15,112 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 6,091 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 216 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 17,017 | 124 | 2,110,108 | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 47,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 144,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 2,835 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-07-15 | D | 4,418 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Squarer | Director | 2026-07-15 | D | 6,281 | — | — | Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-07-15 | D | 6,119 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-07-15 | D | 6,091 | — | — | Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-07-15 | D | 1,324 | 124 | 164,176 | Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 68,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-07-15 | D | 3,444 | — | — | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 33,646 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 84,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 22,933 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 8,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 131,637 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 14,350 | — | — | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 44,433 | 124 | 5,509,692 | Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 8,361 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 3,444 | — | — | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 4,147 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 3,789 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 43,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 43,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 2,717,627 | 124 | 336,985,748 | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 2,717,627 | 124 | 336,985,748 | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 3,444 | 124 | 427,056 | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 650,000 | 124 | 80,600,000 | Common, indirect | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 8,299,225 | 124 | 1,029,103,900 | Common, indirect | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 8,299,225 | 124 | 1,029,103,900 | Common, indirect | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James E. Flynn | Director | 2026-07-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | A | 14,350 | 0 | 0 | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-07-15 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 3,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Darlene Noci | Chief Development Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 107,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 303,105 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexandra Balcom | Chief Financial Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| James Porter | Director | 2026-07-15 | D | 161,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cameron Wheeler | Director | 2026-07-15 | D | 43,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grant C. Bogle | Director | 2026-07-15 | D | 3,714 | 124 | 460,536 | Common | Form 4 ↗ |
| Deborah Miller | Chief Legal Officer | 2026-07-15 | D | 41,100 | — | — | Common | Form 4 ↗ |
| Henry E. Pelish | Chief Scientific Officer | 2026-07-15 | D | 21,073 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 8,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Lane | See Remarks | 2026-07-15 | D | 7,120 | — | — | Common | Form 4 ↗ |
| Christopher Turner | Chief Medical Officer | 2026-07-15 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael L. Meyers | Director | 2026-07-15 | D | 5,146 | 124 | 638,104 | Common | Form 4 ↗ |
Sources (249 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, James Porter. DEF 14A, filed 2026-04-28. Section “Summary Compen sation Table - 2025” · page 37. As printed: 11,393,602. View filing ↗
- Section 01, Christopher Turner. DEF 14A, filed 2026-04-28. Section “Summary Compen sation Table - 2025”. As printed: 4,239,298. View filing ↗
- Section 01, Alexandra Balcom. DEF 14A, filed 2026-04-28. Section “Summary Compen sation Table - 2025”. As printed: 4,170,614. View filing ↗
- Section 01, Darlene Noci. DEF 14A, filed 2026-04-28. Section “Summary Compen sation Table - 2025”. As printed: 4,158,140. View filing ↗
- Section 01, Deborah Miller. DEF 14A, filed 2026-04-28. Section “Summary Compen sation Table - 2025”. As printed: 4,157,524. View filing ↗
- Section 03, James Porter RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Alexandra Balcom RSU. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 03, Deborah Miller RSU. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 03, James Porter OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Darlene Noci RSU. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Turner RSU. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 03, Darlene Noci OPTION. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 03, Alexandra Balcom OPTION. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Turner OPTION. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 03, Deborah Miller OPTION. DEF 14A, filed 2026-04-28. Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 21 : 1. View filing ↗
- Section 08, Matthew Shair, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 639,421. View filing ↗
- Section 08, Christy Oliger. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 627,666. View filing ↗
- Section 08, Ron Squarer. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 602,452. View filing ↗
- Section 08, Anna Protopapas. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 485,432. View filing ↗
- Section 08, Sapna Srivastava, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 461,932. View filing ↗
- Section 08, Cameron A. Wheeler, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 454,762. View filing ↗
- Section 08, Michael L. Meyers, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 451,932. View filing ↗
- Section 08, Grant C. Bogle. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 449,927. View filing ↗
- Section 08, Joseph Pearlberg, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 446,932. View filing ↗
- Section 08, Gary Gilliland, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 322,222. View filing ↗
- Section 08, Emily Drabant Conley, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 49,499. View filing ↗
- Section 08, Andrew A. F. Hack, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 24,285. View filing ↗
- Section 08, James R. Porter, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, James Porter 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grant C. Bogle 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christy Oliger 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-09. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grant C. Bogle 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grant C. Bogle 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grant C. Bogle 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christy Oliger 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christy Oliger 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christy Oliger 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sapna Srivastava 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James E. Flynn 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene Noci 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Balcom 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Porter 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Wheeler 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grant C. Bogle 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Miller 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry E. Pelish 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Benjamin Lane 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Turner 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael L. Meyers 2026-07-15. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: 97.47% (votes for as printed: 68,898,711). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 83.79% (votes for as printed: 53,520,192). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 97.68% (votes for as printed: 55,798,941). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 496,230 + equity 1,999,410 + all other 200,000 = 2,695,640, summed across the director compensation table rows.
- Summit Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Summit Therapeutics Inc.'s own proxy. As printed: 246,047,279. View filing ↗
- Arcellx, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx, Inc.'s own proxy. As printed: 21,402,668. View filing ↗
- Immunovant, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- Revolution Medicines, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. View filing ↗
- Vaxcyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. View filing ↗
- Avidity Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Avidity Biosciences, Inc.'s own proxy. As printed: 14,176,480. View filing ↗
- Cytokinetics, Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics, Incorporated's own proxy. As printed: 11,881,456. View filing ↗
- Nuvalent, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Nuvalent, Inc.'s own proxy. As printed: 11,393,602. View filing ↗
- Arrowhead Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. View filing ↗
- Crispr Therapeutics AG, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics AG's own proxy. As printed: 7,678,477. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Section 10a, Immunovant, Inc. reciprocity. DEF 14A. Immunovant, Inc. names Nuvalent, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Revolution Medicines, Inc. reciprocity. DEF 14A. Revolution Medicines, Inc. names Nuvalent, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗